Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival

from TheBrief.Health · host TheBrief.Health

Adding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.

Episode metadata supplied by the publisher feed · Published Mar 10, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival

0:00 1:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on March 10, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!